Literature DB >> 15850846

Osteoporosis associated with excess glucocorticoids.

Joseph L Shaker1, Barbara P Lukert.   

Abstract

Excess glucocorticoids, whether endogenous or exogenous, can cause osteoporosis and fractures. Even low doses of oral glucocorticoids and mild endogenous hypercortisolism may be associated with bone loss. Patients treated with glucocorticoids, however, often are not evaluated and treated for this problem. Patients on chronic glucocorticoids or initiating these drugs should have their bone density measured and appropriate laboratory studies. They should be treated with adequate calcium and vitamin D, and antiresorptive therapy (particularly bisphosphonates) should be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15850846     DOI: 10.1016/j.ecl.2005.01.014

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  21 in total

Review 1.  Pros and cons of screening for occult Cushing syndrome.

Authors:  Antoine Tabarin; Paul Perez
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

2.  Glucocorticoid-induced osteoporosis: treatment update and review.

Authors:  Lisa-Ann Fraser; Jonathan D Adachi
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

3.  Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study.

Authors:  U Massafra; S Migliaccio; C Bancheri; F Chiacchiararelli; F Fantini; F Leoni; L S Martin; A Migliore; B Muccifora; C Napolitano; R Pastore; A Ragno; S Ronzoni; M Rotondi; M Tibaldi; P Villa; V Vinicola; E D'Erasmo; P Falaschi; G Minisola
Journal:  J Endocrinol Invest       Date:  2012-03-06       Impact factor: 4.256

4.  Rapid loss of bone mass and strength in mice after abdominal irradiation.

Authors:  Dan Jia; Dana Gaddy; Larry J Suva; Peter M Corry
Journal:  Radiat Res       Date:  2011-08-22       Impact factor: 2.841

5.  An unusual case of hypercortisolism with multiple weight-bearing bone fractures.

Authors:  Georgios Papadakis; Brigitte Uebelhart; Michel Goumaz; Sophie Zawadynski; Rene Rizzoli
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

6.  Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.

Authors:  C C Mok; K H Tong; C H To; Y P Siu; K M Ma
Journal:  Osteoporos Int       Date:  2007-11-24       Impact factor: 4.507

Review 7.  Skeletal involvement in adult patients with endogenous hypercortisolism.

Authors:  I Chiodini; M Torlontano; V Carnevale; V Trischitta; A Scillitani
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

8.  Tenofovir-associated bone density loss.

Authors:  Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Kim C Mansky
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

9.  Osteoporosis prophylaxis in patients receiving chronic glucocorticoid therapy.

Authors:  Mir Sadat-Ali; Abdulmohsen H Alelq; Badar A Alshafei; Haifa A Al-Turki; Mohammed A Abujubara
Journal:  Ann Saudi Med       Date:  2009 May-Jun       Impact factor: 1.526

Review 10.  Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors:  Arnulf Langhammer; Siri Forsmo; Unni Syversen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.